A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
about
Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorderAntipsychotics in the treatment of autismEvidence-based comprehensive treatments for early autismRisperidone for autism spectrum disorderMedications for adolescents and young adults with autism spectrum disorders: a systematic reviewOff-label indications for atypical antipsychotics: A systematic reviewAggression in autism spectrum disorder: presentation and treatment optionsOxytocin for Male Subjects with Autism Spectrum Disorder and Comorbid Intellectual Disabilities: A Randomized Pilot Study.Template to Perpetrate: An Update on Violence in Autism Spectrum DisorderAutism spectrum disorders: early detection, intervention, education, and psychopharmacological managementThe status of pharmacotherapy for autism spectrum disordersRisperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J miceMedication treatment in subjects with autistic spectrum disorders.Physical mapping of the serotonin 5-HT(7) receptor gene (HTR7) to chromosome 10 and pseudogene (HTR7P) to chromosome 12, and testing of linkage disequilibrium between HTR7 and autistic disorder.Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report.A systematic review of the use of atypical antipsychotics in autism.Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders.Pharmacotherapeutic management of autism.New directions in the treatment of autism spectrum disorders from animal model research.Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.Childhood epilepsy in relation to mental handicap and behavioural disorders.Developing drugs for core social and communication impairment in autism.Neuropsychiatric problems in tuberous sclerosis complex.Genetic Variants of Angiotensin-Converting Enzyme Are Linked to Autism: A Case-Control Study.Autism spectrum disorders: emerging pharmacotherapy.Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders.Neurotoxic syndrome induced by clomipramine plus risperidone in a patient with autistic spectrum disorder: serotonin or neuroleptic malignant syndrome?Risperidone in pervasive developmental disorders.DRD2 and PPP1R1B (DARPP-32) polymorphisms independently confer increased risk for autism spectrum disorders and additively predict affected status in male-only affected sib-pair families.Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.Role of risperidone in children with autism spectrum disorder.The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities.Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trialPrefrontal activation during inhibitory control measured by near-infrared spectroscopy for differentiating between autism spectrum disorders and attention deficit hyperactivity disorder in adults.Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems.Issues in the management of challenging behaviours of adults with autism spectrum disorder.Psychopharmacology of autism spectrum disorders: a selective review.An update on medication management of behavioral disorders in autism.Clinical and pharmacokinetic evaluation of risperidone for the management of autism spectrum disorder.
P2860
Q22241792-696C2348-5E86-4DFB-ADB3-2D56EF9D307EQ22241891-2D73688F-62D6-4BC2-A480-31B560F9DE8FQ22242991-8D1B1692-1B86-4318-ABAD-FFDA82031203Q24246471-732321FC-FC58-42EE-9317-560DF43B44EFQ24563705-7AC2EFC0-1635-430C-B8D5-D4819486593AQ24803302-0D1BE9FA-3844-48A7-9F8C-C7F24048983CQ26744346-F5324C3A-3C36-45AE-9F3E-66D45C70266CQ27303760-126815D5-2AF8-4050-9536-76E9D2FB64C0Q28079993-5CBFA2FD-4DDF-4C5F-B374-E858C1BF962EQ28212094-97D1B40D-898A-4581-83F9-B02D00D5F927Q28239931-04E9842D-7EE7-432F-82D0-F671D695CE88Q28397643-8369A7E4-C802-488E-B11B-E4BF690A421CQ30623213-A8216B00-F230-4C68-8164-34CB126CEF55Q33874461-D32F0FF3-695D-4425-81FB-90BF2171012AQ33891726-6E34E44A-1A92-497F-BE25-F37A01893C68Q33958570-403B2521-A757-4DE0-81B2-6FB49384F271Q34177643-5CE7F765-E61C-44C3-95A6-719D4453E21CQ34240955-9D64CB59-6D14-4AA1-9BCE-506AC8C6F324Q34267391-6B877616-8455-4619-800C-538CB8AC9ADFQ34427552-CBC0A746-C610-4969-8F3F-357698C7F34EQ34540188-5DBA4AF1-1C3B-49FF-8281-9664680999A9Q34822538-C56EB911-E8C3-4B83-A2A2-8852C4677808Q35783807-5F6A9BCD-D98C-4249-A3BB-A7C89006BDA1Q35991106-47A47E9F-EC3E-4273-925C-AA6C93730FD5Q36219642-ED6A8B83-EEA0-4906-BD5E-561992A959E8Q36258557-170BF823-0480-41BB-9A11-9756159EE714Q36292942-BF6E6008-4C47-44D9-9BC8-3F548DE45D38Q36307844-D629E72D-83ED-4E5A-88E7-36C6440229D7Q36342328-3C05EE33-B849-450C-81A4-45BE285B6B9BQ36443014-C12CFA9B-DBB0-4CDE-9865-82C1EB286DECQ36473542-49BBCCD7-CB15-49C0-A649-FCDE70E7C4DEQ36930937-728EFF74-3DA5-4A18-A5C9-1F5CD7295357Q37019876-B5096B36-5EDC-4C9B-BE65-01148A8C1942Q37347460-24A25B6A-632A-4103-939D-F6EA7F2F405DQ37595835-2D296A75-01FA-4B64-B1C7-F4BDFB72AFBAQ37820701-29428659-7C46-429E-AF93-4F81637A3220Q37893637-E7C947F5-0C8C-4032-863F-0CCD003F96FCQ38034655-C629326A-BBF7-40AB-B407-225924278456Q38184482-C5E83EC3-C4F1-4077-8CFA-51DCB312037FQ38266796-8422BD99-E442-4290-9734-B04C64653FF9
P2860
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
A double-blind, placebo-contro ...... asive developmental disorders.
@en
A double-blind, placebo-contro ...... asive developmental disorders.
@nl
type
label
A double-blind, placebo-contro ...... asive developmental disorders.
@en
A double-blind, placebo-contro ...... asive developmental disorders.
@nl
prefLabel
A double-blind, placebo-contro ...... asive developmental disorders.
@en
A double-blind, placebo-contro ...... asive developmental disorders.
@nl
P2093
P921
P1433
P1476
A double-blind, placebo-contro ...... asive developmental disorders.
@en
P2093
P304
P356
10.1001/ARCHPSYC.55.7.633
P407
P577
1998-07-01T00:00:00Z